Charles River Laboratories International, Inc. (CRL) Profit Margins
Over the twelve months to 2026-06-30, Charles River Laboratories International, Inc. (CRL) had operating margin 2.3%, net margin -6.0%, free cash flow margin 9.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRLCharles River Laboratories International, Inc.Follow CRL — free
—
Price chart with a free account
- Market cap
- 16.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.3% | 58.7% | 57.5% | 57.3% | 57.0% | 58.3% | 54.9% | 53.4% | — | — | — | — | — | — | — | — | — | |
| Operating margin | -26.3% | 15.3% | 14.7% | 13.0% | 13.7% | 15.1% | 14.1% | 15.5% | 14.6% | 13.4% | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% | 2.3% | |
| Net margin | -29.7% | 9.6% | 8.7% | 8.8% | 9.8% | 11.0% | 9.2% | 6.6% | 10.0% | 9.6% | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% | -6.0% | |
| FCF margin | 11.1% | 13.8% | 14.2% | 14.6% | 15.0% | 17.9% | 15.6% | 12.7% | 13.3% | 13.0% | 13.0% | 15.0% | 7.4% | 8.8% | 12.4% | 12.9% | 9.3% |
USD billions · SEC XBRL
Charles River Laboratories International, Inc. — questions
- What is Charles River Laboratories International, Inc.'s operating margin?
- 2.3% over the twelve months to 2026-06-30.
- What is Charles River Laboratories International, Inc.'s net profit margin?
- -6.0% over the twelve months to 2026-06-30.
Every figure on this page comes from Charles River Laboratories International, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.